We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
+6.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.78B
AUM Growth
+$215M
Cap. Flow
-$396M
Cap. Flow %
-22.17%
Top 10 Hldgs %
44.5%
Holding
325
New
107
Increased
59
Reduced
54
Closed
92

Top Buys

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$13.1M
2
BPTH
Bio-Path Holdings Inc
BPTH
+$10.3M
3
OPK icon
Opko Health
OPK
+$7.29M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$6.72M
5
GILD icon
Gilead Sciences
GILD
+$6.04M

Top Sells

Rank Stock Value
1
MNKD icon
MannKind Corp
MNKD
+$22.4M
2
ABUS icon
Arbutus Biopharma
ABUS
+$9.33M
3
MDVN
MEDIVATION, INC.
MDVN
+$5.53M
4
AEGR
Aegerion Pharmaceuticals
AEGR
+$4.82M
5
TEVA icon
Teva Pharmaceuticals
TEVA
+$4.69M

Sector Composition

Rank Sector Weight
1 Healthcare 10.45%
2 Energy 0.15%
3 Communication Services 0%
4 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
76
PUT
Novavax
NVAX
$1.21B
$3.6M 0.2%
397
+301
+314% +$33.6K
PLUR icon
77
PUT
Pluri
PLUR
$18.1M
$3.55M 0.2%
120
+107
+823% +$34.5K
EPZM
78
DELISTED
Epizyme, Inc
EPZM
$3.44M 0.19%
+151,220
New +$4.58M
BDSI
79
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3.33M 0.19%
+3,952
New +$31.9K
SGMO
80
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$3.21M 0.18%
+177,265
New +$3.42M
TPST icon
81
Tempest Therapeutics
TPST
$13.9M
$3.19M 0.18%
122
+70
+135% +$1.98M
RXII
82
PUT
DELISTED
GALENA BIOPHARMA INC COM
RXII
$2.95M 0.17%
11,782
+2,661
+29% +$665K
TSRO
83
DELISTED
TESARO, Inc.
TSRO
$2.9M 0.16%
+98,500
New +$3.1M
TNXP icon
84
Tonix Pharmaceuticals
TNXP
$158M
– –
0
– –
KERX
85
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$2.86M 0.16%
+167,999
New +$2.53M
RXDX
86
DELISTED
Ignyta, Inc.
RXDX
$2.84M 0.16%
+341,810
New +$3.2M
LGND icon
87
CALL
Ligand Pharmaceuticals
LGND
$5.94B
$2.83M 0.16%
673
-1,797
-73% -$74.9K
PBYI icon
88
PUT
Puma Biotechnology
PBYI
$406M
$2.82M 0.16%
+271
New +$31.9K
TLPH icon
89
PUT
Talphera
TLPH
$67.5M
$2.79M 0.16%
+116
New +$27.5K
ECYT
90
PUT
DELISTED
Endocyte, Inc. Common Stock
ECYT
$2.79M 0.16%
1,170
+260
+29% +$3.77K
MDVN
91
CALL
DELISTED
MEDIVATION, INC.
MDVN
$2.77M 0.16%
+860
New +$31.7K
IOC
92
DELISTED
Interoil Corporation
IOC
$2.74M 0.15%
+42,361
New +$2.34M
CELG
93
DELISTED
Celgene Corp
CELG
$2.72M 0.15%
+38,998
New +$3.09M
CVM.WS
94
DELISTED
Cel-Sci Corp Series S
CVM.WS
$2.68M 0.15%
+6,316,000
New +$2.61M
IMNN icon
95
PUT
Imunon
IMNN
$6.43M
$2.55M 0.14%
3
– –
INSM icon
96
CALL
Insmed
INSM
$22.6B
$2.48M 0.14%
1,302
-689
-35% -$13.1K
AMRN
97
Amarin Corp
AMRN
$293M
$2.39M 0.13%
66,081
+60,891
+1,173% +$2.26M
SSKN
98
DELISTED
Strata Skin Sciences
SSKN
$2.32M 0.13%
7,449
-1,132
-13% -$398K
BLUE
99
DELISTED
bluebird bio
BLUE
$2.31M 0.13%
7,858
-19
-0.2% -$5.76K
ANTH
100
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$2.31M 0.13%
86,005
-128,365
-60% -$3.26M
2 3
4
5 6

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q1 2014 Portfolio in Review

As of Q1 2014, Sabby Management held 325 positions worth $1.78B, up 14% from $1.57B the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Sabby Management withdrew a net $396M in Q1 2014, closing 92 positions and reducing 54 holdings. Its most notable exit was MannKind Corp, an estimated $22.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, up from 9.1% a quarter earlier, followed by Energy and Communication Services.

Against the trend, Sabby Management opened a new position in Tenax Therapeutics worth $11.8M.

  • Sabby Management's largest Q1 2014 buy was Tenax Therapeutics: 66 shares worth $11.8M.
  • Sabby Management added most to Gilead Sciences in Q1 2014, an estimated $6.04M increase.
  • Sabby Management's biggest Q1 2014 reduction was Aegerion Pharmaceuticals, cutting an estimated $4.82M.
  • Sabby Management fully exited MannKind Corp in Q1 2014, selling an estimated $22.4M.
  • Sabby Management's ten largest holdings make up 44% of its $1.78B portfolio in Q1 2014.
  • Sabby Management opened 107 new positions and closed 92 in Q1 2014.
  • Sabby Management's portfolio value rose 14% quarter-over-quarter to $1.78B.

Based on Sabby Management's 13F filing for Q1 2014, filed 14 May 2014.